B. Bennett

发表

Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study

C. Tzourio, B. Falissard, F. Cotté, 2020, Journal of medical Internet research.

Improving patient-clinician communication following nephrectomy in renal cell carcinoma: Development, content validation and pilot testing of a conversation aid tool.

M. Staehler, E. Brohan, G. Stewart, 2020, Patient education and counseling.

Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet Syndrome

S. Auvin, C. Chiron, R. Nabbout, 2018, Epilepsy & Behavior.

Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model

J. Cramer, B. Bennett, A. Towse, 2014, Current medical research and opinion.

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

D. Matei, J. Ledermann, C. Scott, 2016, British Journal of Cancer.

A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm

T. Ziemssen, F. Dahlke, B. Bennett, 2020, JMIR medical informatics.

Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: A web-based survey

M. Neary, E. Brohan, B. Bennett, 2019, Epilepsy & Behavior.

Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report.

L. McLeod, O. Chassany, M. Schlichting, 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Quality of life in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus in CheckMate 025, a randomised, phase 3 clinical trial

R. Motzer, D. Cella, H. Dastani, 2017 .

B. Bennett, M. Schwenkglenks, B. Rosenkranz, 2016, Health and Quality of Life Outcomes.

Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe

B. Bennett, M. Daumont, G. Taylor‐Stokes, 2022, BMC cancer.

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.

R. Motzer, D. Cella, H. Dastani, 2016, The Lancet. Oncology.

Methods for Measuring Multiple Medication Adherence: A Systematic Review-Report of the ISPOR Medication Adherence and Persistence Special Interest Group.

M. Hiligsmann, D. Hutchins, J. Zeber, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study

M. Freedman, T. Ziemssen, F. Dahlke, 2020, Journal of medical Internet research.

Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique

T. Maher, B. Bennett, M. Whyte, 2015, Advances in Therapy.

Short bowel syndrome and the impact on patients and their families: a qualitative study.

S. Burden, B. Bennett, S. Lal, 2020, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

B. Bennett, M. Schwenkglenks, B. Rosenkranz, 2017, PloS one.

How to Evaluate Health-Related Quality of Life and Its Association with Medication Adherence in Pulmonary Tuberculosis – Designing a Prospective Observational Study in South Africa

B. Bennett, M. Schwenkglenks, B. Rosenkranz, 2016, Front. Pharmacol..

The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature

J. Penrod, B. Bennett, Yong Yuan, 2016, Front. Pharmacol..

Psychometric Validation of the Heart Failure Caregiver Questionnaire (HF-CQ®)

A. Strömberg, T. Jaarsma, M. Chung, 2017, The Patient - Patient-Centered Outcomes Research.

Measuring Health-Related Quality of Life in Tuberous Sclerosis Complex – Psychometric Evaluation of Three Instruments in Individuals With Refractory Epilepsy

M. Neary, E. Brohan, R. Nabbout, 2018, Front. Pharmacol..

Association between Health-Related Quality of Life and Medication Adherence in Pulmonary Tuberculosis in South Africa

B. Bennett, M. Schwenkglenks, B. Rosenkranz, 2017, Front. Pharmacol..

Content Validity of a Willingness to Quit Tool for Use with Current Smokers in Clinical Practice

E. Brohan, B. Bennett, B. Emir, 2017, Advances in Therapy.

Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe

B. Bennett, G. Taylor‐Stokes, S. Curtis, 2021, BMC cancer.

D. Matei, J. Ledermann, C. Scott, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms

J. Brazier, A. Pickard, L. Longworth, 2021, The European Journal of Health Economics.

Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057

H. Dastani, R. Gralla, J. Penrod, 2016 .

Real-World Treatment Patterns and Outcomes in Patients with Head and Neck Cancer: Point-in-Time Survey of Oncologists in Italy and Spain

B. Bennett, M. Contente, Prianka Singh, 2021, Advances in Therapy.

Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.

H. Dastani, R. Gralla, J. Penrod, 2018, European journal of cancer.

A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.

M. King, J. Shaw, A. Trigg, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.

T. Ziemssen, B. Bennett, D. Tomic, 2019, Multiple sclerosis and related disorders.

Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study (Preprint)

C. Tzourio, B. Falissard, F. Cotté, 2020 .

Caregivers of patients with malignant pleural mesothelioma: who provides care, what care do they provide and what burden do they experience?

B. Bennett, M. Daumont, Adam Moore, 2023, Quality of Life Research.

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

A. Mansfield, S. Peters, A. Tsao, 2022, Lung cancer.

First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743

S. Peters, A. Tsao, P. Baas, 2021, Pneumologie.

Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

E. Winquist, R. Metcalf, B. Bennett, 2023, Cancers.

PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057.

H. Dastani, R. Gralla, J. Penrod, 2016, Journal of Thoracic Oncology.

Quality of life (QoL) and overall survival (OS) in patients (pts) with advanced clear-cell renal cell carcinoma (aRCC) treated with nivolumab (NIVI) vs. everolimus (EVE) in the phase III CheckMate 025 study.

R. Motzer, D. Cella, H. Dastani, 2016 .